Physician profile
Doris Appiah
NPI 1326661489
$2,597.13
in general payments reported to CMS, 2019-2025
17 companies · $743 in 2025
The $743 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $417 · 2024: $1,437 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,517 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.14 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $800.84 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $639.64 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Astellas Pharma US INC | $204.49 | 2024-2025 | Veozah |
| Lilly USA, LLC | $191.42 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $157.20 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $104.89 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.09 | 2023-2024 | Cycloset, Trulance, Xifaxan |
| Exact Sciences Corporation | $78.53 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $71.60 | 2024 | |
| Phathom Pharmaceuticals, INC. | $55.76 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.24 | 2023-2025 | Jardiance, Synjardy |
| Inspire Medical Systems, INC. | $33.33 | 2024 | Inspire |
| Amgen INC. | $29.18 | 2025 | Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.46 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $22.86 | 2023 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $22.70 | 2025 | Xelstrym |
| Esperion Therapeutics, INC. | $16.90 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Appiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.